NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $10.22 -0.20 (-1.87%) As of 07/3/2025 01:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeuroPace Stock (NASDAQ:NPCE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeuroPace alerts:Sign Up Key Stats Today's Range$10.24▼$10.6450-Day Range$10.23▼$18.1352-Week Range$5.45▼$18.98Volume84,321 shsAverage Volume181,467 shsMarket Capitalization$335.38 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingModerate Buy Company Overview NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. Read More NeuroPace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreNPCE MarketRank™: NeuroPace scored higher than 59% of companies evaluated by MarketBeat, and ranked 1273rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 3 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 37.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently increased by 0.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.56% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently increased by 0.25%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NeuroPace this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,664,956.00 in company stock.Percentage Held by Insiders20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJuly 2 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 27, 2025 | prnewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.July 4 at 2:00 AM | Traders Agency (Ad)NeuroPace Announces Strategic CFO Transition - MorningstarJune 26, 2025 | morningstar.comMNeuroPace, Inc.: NeuroPace Announces Strategic CFO TransitionJune 25, 2025 | finanznachrichten.deAnalysts Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $15.50June 25, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - MorningstarJune 24, 2025 | morningstar.comMNeuroPace Announces Strategic CFO TransitionJune 24, 2025 | globenewswire.comSee More Headlines NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $11.19 at the start of the year. Since then, NPCE shares have decreased by 8.6% and is now trading at $10.2250. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. The business earned $22.52 million during the quarter, compared to analysts' expectations of $21.85 million. NeuroPace had a negative trailing twelve-month return on equity of 190.84% and a negative net margin of 29.42%. Read the conference call transcript. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroPace own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today7/04/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NPCE CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+51.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.14 million Net Margins-29.42% Pretax Margin-29.42% Return on Equity-190.84% Return on Assets-25.08% Debt Debt-to-Equity Ratio2.46 Current Ratio6.63 Quick Ratio5.70 Sales & Book Value Annual Sales$79.91 million Price / Sales4.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book37.87Miscellaneous Outstanding Shares32,800,000Free Float26,075,000Market Cap$335.38 million OptionableOptionable Beta1.93 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:NPCE) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NPCE Stock Alerts